Statera Biopharma, Inc.
STABOTCHealthcare● Active
$0.00
+$0.00(+0.00%)
Market Cap$7142
P/E Ratio—
52W High$0.0266
52W Low$0.0001
Statera Biopharma, Inc. (STAB) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
STAB · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2022Report Date: Nov 14, 2022EPS Actual
-$0.07
Revenue
$0.00B
Fiscal Period
Q4 FY2022
FY ends December
Report Date
Nov 14, 2022
After Market Close
STAB reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.02
Rev. $0.33B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.02
Rev. Est.$0.33B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2024 | Jun 14, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 17, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Feb 12, 2024 | — | — | — | — | — | — |
| ◌ Q3 FY2023 | Sep 8, 2023 | — | — | — | — | — | — |
| ◌ Q3 FY2023 | Aug 29, 2023 | — | — | — | — | — | — |
| ◌ Q2 FY2023 | May 29, 2023 | — | — | — | — | — | — |
| ◌ Q1 FY2023 | Feb 13, 2023 | — | — | — | — | — | — |
| — Q4 FY2022 | Nov 14, 2022 | — | -$0.07 | — | $0.00B | — | — |
Q2 FY2024
Jun 14, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 17, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Feb 12, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Sep 8, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 29, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2023
May 29, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2023
Feb 13, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2022
Nov 14, 2022
EPS Actual
-$0.07
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 1 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $1.39 | $1.39 | $1.39 | 1 |
| Q2 FY2023 | $1.19 | $1.19 | $1.19 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q4 FY2022 | Nov 14, 2022 | — | $0.11 | $0.11 | -3.22% |
| — Q4 FY2022 | Oct 28, 2022 | — | $0.15 | $0.15 | -2.55% |
| — Q4 FY2022 | Oct 21, 2022 | — | $0.15 | $0.17 | +8.15% |
| — Q4 FY2022 | Oct 5, 2022 | — | $0.13 | $0.14 | +7.85% |
| — Q4 FY2021 | Nov 15, 2021 | — | $4.08 | $4.02 | -1.47% |
Q4 FY2022-3.22%
Report Date
Nov 14, 2022
EPS Beat/Miss
—
Price Before
$0.11
Price After
$0.11
Q4 FY2022-2.55%
Report Date
Oct 28, 2022
EPS Beat/Miss
—
Price Before
$0.15
Price After
$0.15
Q4 FY2022+8.15%
Report Date
Oct 21, 2022
EPS Beat/Miss
—
Price Before
$0.15
Price After
$0.17
Q4 FY2022+7.85%
Report Date
Oct 5, 2022
EPS Beat/Miss
—
Price Before
$0.13
Price After
$0.14
Q4 FY2021-1.47%
Report Date
Nov 15, 2021
EPS Beat/Miss
—
Price Before
$4.08
Price After
$4.02
Beat Rate0 / 5 quarters
Largest Move+8.15% (Q4 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: STAB ends December
Statera Biopharma, Inc. (STAB) most recently reported earnings on November 14, 2022 for Q4 FY2022, posting EPS of $-0.07 (in line with the analyst consensus of —). The next STAB earnings date is expected around September 1, 2026.
Each quarter, investors track STAB earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. STAB revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
STAB's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
STAB earnings · 4 questionsStatera Biopharma, Inc.'s next earnings report is expected around September 1, 2026. STAB typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; STAB historically reports after market close (AMC).
STAB earnings datewhen is STAB earningsSTAB next earnings datewhen does STAB report earningsSTAB earnings calendar
▸ Source: FMP · Statera Biopharma, Inc. SEC filings · US GAAP · Statera Biopharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026